Document:

<PAGE>   1
                                                                    Exhibit 10.2

                             AMENDMENT TO AGREEMENT

     This Amendment to Agreement (the "Agreement") is made by and between
Network Healthcare Holdings Limited ("NETCARE") Tshepo Pharmaceuticals (Pty)
Limited ("TSHEPO"), and BIOPURE Corporation ("BIOPURE").

     WHEREAS, NETCARE and BIOPURE are parties to an agreement called
"Appointment of Network Healthcare Holdings Limited (NETCARE) as the Sole
Distributor with the Exclusive Rights of BIOPURE Product for South Africa" (as
amended hereby, "the Agreement") in which NETCARE has been appointed the sole
Distributor with exclusive rights of BIOPURE PRODUCT for South Africa ("the
Territory");

     WHEREAS, In clauses 13.2 and 13.3 of the AGREEMENT, NETCARE has undertaken
unto and in favour of BIOPURE, among other things, to use its best endeavors to
assist BIOPURE in obtaining registration of the PRODUCT in South Africa;

     WHEREAS, In order to facilitate registration of the PRODUCT, NETCARE has
entered into a Joint Venture Agreement with Superbia Three (Pty) Limited
(SUPERBIA), pursuant to which NETCARE and SUPERBIA have registered TSHEPO,
Registration Number 2000/012141/07, which is owned by NETCARE and SUPERBIA; and

     WHEREAS, NETCARE wishes to assign all of its rights under the Agreement to
TSHEPO and to amend the Agreement and BIOPURE is willing to agree to the
assignment and amendment on the terms and subject to the conditions hereinafter
set forth;

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
herein contained, the parties agree as follows:-

<PAGE>   2

     1.   NETCARE has assigned or ceded and does hereby assign or cede to TSHEPO
all of NETCARE's rights and benefits under the Agreement.

     2.   TSHEPO accepts such assignment and cession and agrees to be bound by
and to perform the obligations of NETCARE under the Agreement.

     3.   NETCARE binds itself as surety and co-principal debtor unto and in
favour of BIOPURE and indemnifies and holds harmless BIOPURE in respect of any
action of any nature whatsoever that may arise out of the performance by TSHEPO
under the Agreement and undertakes to remain liable and responsible for and to
ensure performance by TSHEPO of its obligations as contained in the Agreement.

     4.   BIOPURE consents to the assignment and assumption described above and
to the agreement of cession entered into by and between NETCARE as cedent and
TSHEPO as cessionary.

     5.   The term "Territory" is hereby amended to mean all countries on the
continent of Africa with the exception of Egypt in accordance, as to expansion
beyond South Africa, with an agreed upon plan.

     6.   The remaining terms and conditions of the Agreement shall remain in
full force and effect.

     IN WITNESS WHEREOF, this Agreement has been duly executed and delivered the
9th day of March, 2001, effective as of July 31 2000.

Witnesses as to                             NETWORK HEALTHCARE
NETCARE:                                    HOLDINGS LIMITED

----------------------------------

                                            By:
----------------------------------             ---------------------------------

                                       2
<PAGE>   3

Witnesses as to
BIOPURE:                                    BIOPURE CORPORATION

----------------------------------
                                            By:

----------------------------------             ---------------------------------

Witnesses as to                             TSHEPO PHARMACEUTICALS
TSHEPO:                                     (PTY) LIMITED

----------------------------------
                                            By:

----------------------------------             ---------------------------------

                                       3<PAGE>   1
                                                                    Exhibit 10.3

                                                     November 1, 2000

Network Healthcare Holdings Limited ("Netcare")
Sanlan Park South
9 Fredman Drive
Sandton, 2196
Republic of South Africa

Gentlemen:

     We have had correspondence and discussions relating to the granting of
warrants for Biopure stock. This letter sets forth the result of our
discussions.

     We will grant the warrants hereinafter described (collectively, the
"Warrants") on the following schedule, but they would only become exercisable
after "South African Approval," meaning a broad label marketing approval for
Hemopure(R) solution, for surgery, in South Africa (i.e., the approval requested
by Biopure in its July 1999 submission to the Medicines Control Council).
Further, all of the Warrants will become exercisable (or, in the case of the
second grant - be issued) only if South African Approval is achieved before U.S.
approval AND on or before December 31, 2001.

     The first Warrant, a Warrant to purchase 150,000 shares of Biopure Class A
Common Stock, will be granted as of October 31, 2000 and will have an exercise
price of $19.304 per share. This Warrant will have a 3-year term and will expire
October 31, 2003.

     The second Warrant, a Warrant to purchase 100,000 shares of Biopure Class A
Common Stock, will be granted as of the day Hemopure receives South African
Approval, as defined above. The exercise price for the second Warrant will be
the average high and low prices reported by NASDAQ, averaged over the trading
days in the six months ending on the day before the date of issuance or, if
higher, $35.00 per share. This Warrant will have a 3-year term from the date of
grant.

     Neither the Warrants nor the shares issued upon exercise of the Warrants
("Shares") will be registered under the U.S. Securities Act of 1933, so the
holder will need to rely on the availability of Rule 144 to sell shares in the
U.S. market. The Warrants will provide for cashless exercise. Thus, assuming
that the current position of the U.S. Securities and Exchange

<PAGE>   2
Network Healthcare Holdings Limited
November 1, 2000
Page 2

Commission as we now understand it does not change, we expect that Shares
acquired for cash may be saleable under Rule 144 one year after the date the
Warrant being exercised was issued, and Shares acquired in a cashless exercise
may be salable at any time beginning one year following the date of issuance of
the Warrant pursuant to which the Shares are issued.

     The grants of the Warrants are to comply with fair, lawful and ethical
business practices. We hope for a favorable outcome to the past efforts by all
parties with our application to the Medicines Control Council. All Warrants will
be in the form attached hereto, with appropriate changes for price, date and
other conforming terms. Netcare has advised us that the Warrants are to be
issued to Netcare International Holdings Limited (Mauritius), Registration No.
19094/3512 ("Mauritius").

     Netcare represents, warrants and agrees as follows:

          (a) Mauritius is wholly owned beneficially and of record by Netcare.

          (b) Except for sales of Shares pursuant to Rule 144, the Warrants may
not be transferred in whole or in part without the prior written approval of
Biopure Corporation in its sole discretion.

          (c) Neither the Warrants nor any Shares may be transferred for
consideration other than fair market value paid in cash.

          (d) Neither Netcare nor Mauritius has promised to, directly or
indirectly (including by transfer of the capital stock of or other interests in
any of Netcare or Mauritius), nor will either of them use, a Warrant or any
portion thereof or any Shares or any proceeds from a Warrant or any Shares (from
disposition, pledge or any other transaction), directly or indirectly (including
derivative securities), or any other payment or benefit derived directly or
indirectly from Biopure Corporation to offer, promise or pay any money, gift or
any other thing of value to any person (i) for the purpose of influencing
official actions or decisions affecting Biopure Corporation or any of its
products, or (ii) while knowing or having reason to

<PAGE>   3
Network Healthcare Holdings Limited
November 1, 2000
Page 3

know that any portion of this money, gift or thing will, directly or indirectly,
be given, offered or promised to (x) an employee, officer or other person acting
in an official capacity for any government or its instrumentalities or (y) any
political party, party official or candidate for political office.

     Netcare will and will cause Mauritius to provide Biopure Corporation with
the assurances and official documents that Biopure Corporation periodically may
request to verify the compliance with paragraph (d).

     This letter is being signed by Biopure Corporation on March 9, 2001 and
will become binding and effective as of the date first set forth above when
agreed to and duly signed by Netcare and delivered to Biopure Corporation.

                                             Sincerely,

                                             BIOPURE CORPORATION

                                             By:________________________________
                                                Carl W. Rausch
                                                Chairman, CEO

AGREED TO:

NETWORK HEALTHCARE HOLDINGS
  LIMITED

By:_______________________________
   Title:<PAGE>   1
                                                                    Exhibit 10.4

                                                   November 1, 2000

Joe Madungandaba
Scanix Six (Pty) Ltd.
Private Bag X34
Benmore 2010
Sanlam Office Park South 9
Fredman Drive
Sandown 2196
Republic of South Africa

Dear Joe:

     We have had correspondence and discussions relating to the granting of
warrants for Biopure stock. This letter sets forth the result of our
discussions.

     We will grant the warrants hereinafter described (collectively, the
"Warrants") on the following schedule, but they would only become exercisable
after "South African Approval," meaning a broad label marketing approval for
Hemopure(R) solution, for surgery, in South Africa (i.e., the approval requested
by Biopure in its July 1999 submission to the Medicines Control Council).
Further, all of the Warrants will become exercisable (or, in the case of the
second and third grants - be issued) only if South African Approval is achieved
before U.S. approval AND on or before December 31, 2001.

     The first Warrant, a Warrant to purchase 250,000 shares of Biopure Class A
Common Stock, will be granted as of October 31, 2000 and will have an exercise
price of $19.304 per share. This Warrant will have a 3-year term and will expire
October 31, 2003.

     The second Warrant, a Warrant to purchase 250,000 shares of Biopure Class A
Common Stock, will be granted as of the day Hemopure receives South African
Approval, as defined above. The exercise price for the second Warrant will be
the average high and low prices reported by NASDAQ, averaged over the trading
days in the six months ending on the day before the date of issuance or, if
higher, $35.00 per share. This Warrant will have a 3-year term from the date of
grant.

     The third Warrant, a Warrant to purchase 250,000 shares of Biopure Class A
Common Stock, will be granted following South African Approval, as defined
above, provided our agreed upon

<PAGE>   2
Phambili Hospital Products (PTY) Ltd.
November 1, 2000
Page 2

development plans are being met but not earlier than October 31, 2001. The
Warrant exercise price will be a six-month daily average, as described above
(the six-month period ending on the day before the date of issuance) or $45.00
per share, whichever is less.

     Neither the Warrants nor the shares issued upon exercise of the Warrants
("Shares") will be registered under the U.S. Securities Act of 1933, so the
holder will need to rely on the availability of Rule 144 to sell shares in the
U.S. market. The Warrants will provide for cashless exercise. Thus, assuming
that the current position of the U.S. Securities and Exchange Commission as we
now understand it does not change, we expect that Shares acquired for cash may
be saleable under Rule 144 one year after the date the Warrant being exercised
was issued, and Shares acquired in a cashless exercise may be salable at any
time beginning one year following the date of issuance of the Warrant pursuant
to which the Shares are issued.

     The grants of the Warrants are to comply with fair, lawful and ethical
business practices. We hope for a favorable outcome to the past efforts by all
parties with our application to the Medicines Control Council. All Warrants will
be in the form attached hereto, with appropriate changes for price, date and
other conforming terms.

     You have advised us that the Warrants are to be issued to a new
corporation, Scanix Six (Pty) Limited, registration no. 2000/029528/07
("Owner"). Because our relationship with the principals of Owner, you and Dr.
Anna Mokgokong, predates the existence of Owner, both of you and Dr. Mokgokong
have agreed to assure us that no other entity has or will have any rights to or
claims on the Warrants. Thus, each of you (Mr. Madungandaba), Dr. Mokgokong,
Malasela Holdings (Pty) Limited (for itself and all of its affiliates), Phambili
Hospital Products (Pty) Limited and Owner agree as follows:

          1. In consideration of the issuance of the Warrants to Owner, and
other good and valuable consideration, receipt of which each of the Undersigned,
jointly and severally, on behalf of himself, herself or itself and his, her or
its heirs, assigns, representatives, administrators, and/or

<PAGE>   3
Phambili Hospital Products (PTY) Ltd.
November 1, 2000
Page 3

executors, hereby release and forever discharge Biopure Corporation and each of
its stockholders, predecessors, successors, assigns, agents, directors,
officers, employees, former employees, representatives, attorneys, divisions,
affiliates and subsidiaries, whether wholly or partially owned and affiliated
(and agents, directors, officers, employees, former employees, representatives,
and attorneys of such divisions, subsidiaries and affiliates), and all persons
acting by, through, under or in concert with any of them (collectively,
"Releasees"), or any of them, from any and all charges, complaints, claims,
liabilities, actions, causes of action, suits, rights, demands, costs, losses,
debts and expenses (including attorneys' fees and costs actually incurred), of
any nature whatsoever, known or unknown ("claim" or "claims"), which he, she or
it now has, owns, or holds, or claims to have own or hold, or which he, she or
it, at any time hereafter had, owned, or held, or claimed to have had, owned or
held against each or any of the Releasees, including without limitation, express
or implied, any claims for breach of contract or implied contract or any claims
for failure to pay in connection with services, including without limitation,
any claim to the issued Warrants or to any other warrants, options, or any
securities or rights to receive securities.

     Each of Owner, Joe Madungandaba and Anna Mokgokong represent, warrant and
agree as follows:

          (a) The sole owner of record and beneficially of Owner is Superbia
Three (Pty) Limited, a South African corporation with registration number
2000/030294/07 ("Superbia").

          (b) The only owners of record and beneficially of Superbia are Kwesa
Investment Trust ("Kwesa") and Kolebe Family Trust ("Kolebe"). These two trusts
are also the only owners of record and beneficially of Malasela Group (Pty)
Limited.

          (c) The beneficiaries of Kwesa are Joe Madungandaba and members of his
family, and none of Mr. Madungandaba or any such family member is a person
described in paragraph f(ii) below. The beneficiaries of Kolebe are Dr. Anna
Mokgokong and members of her family, and none of Dr. Mokgokong or

<PAGE>   4
Phambili Hospital Products (PTY) Ltd.
November 1, 2000
Page 4

any such family member is a person described in paragraph f(ii) below.

          (d) Except for sales of Shares pursuant to Rule 144, the Warrants may
not be transferred in whole or in part without the prior written approval of
Biopure Corporation in its sole discretion.

          (e) Neither the Warrants nor any Shares may be transferred for
consideration other than fair market value paid in cash.

          (f) None of the undersigned nor any trustee or beneficiary of Kwesa or
Kolebe has promised to, directly or indirectly (including by transfer of the
capital stock of or other interests in any of the undersigned or any changes in
or assignments of trust interests by a trustee or any beneficiary of Kwesa or
Kolebe), nor will any of the Undersigned use, a Warrant or any portion thereof
or any Shares or any proceeds from a Warrant or any Shares (from disposition,
pledge or any other transaction), directly or indirectly (including derivative
securities), or any other payment or benefit derived directly or indirectly from
Biopure Corporation to offer, promise or pay any money, gift or any other thing
of value to any person (i) for the purpose of influencing official actions or
decisions affecting Biopure Corporation or any of its products, or (ii) while
knowing or having reason to know that any portion of this money, gift or thing
will, directly or indirectly, be given, offered or promised to (x) an employee,
officer or other person acting in an official capacity for any government or its
instrumentalities or (y) any political party, party official or candidate for
political office.

     Each of the undersigned, as applicable, will provide Biopure Corporation
with the assurances and official documents that Biopure Corporation periodically
may request to verify the Undersigned's compliance with paragraph (f).

     This letter is being signed by Biopure Corporation on March 9, 2001 and
will become binding and effective as of the date first set forth above when
agreed to and duly signed by all

<PAGE>   5
Phambili Hospital Products (PTY) Ltd.
November 1, 2000
Page 5

of the undersigned by duly authorized persons and delivered to Biopure
Corporation.

                                             Sincerely,

                                             BIOPURE CORPORATION

                                             By:________________________________
                                                Carl W. Rausch
                                                Chairman, CEO

AGREED TO:

Phambili Hospital Products
  (Pty) Limited (as to
  paragraph numbered 1)

By:_______________________________           ___________________________________
   Title:                                    Joe Madungandaba

<PAGE>   6
Phambili Hospital Products (PTY) Ltd.
November 1, 2000
Page 6

Malasela Holdings (Pty) Limited
(as to paragraph numbered 1)

                                             ___________________________________
                                             Dr. Anna Mokgokong
By:_______________________________
   Title:
                                             Scanix Six (Pty) Limited

                                             By:________________________________
                                                Title:

Superbia Three (Pty) Limited

By:_______________________________

   Kwesa Investment Trust

By:_______________________________
   Trustee

Kolebe Family Trust

By:_______________________________
   Trustee

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00026-of-00352.parquet"}]]